SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:umu-191071"
 

Search: onr:"swepub:oai:DiVA.org:umu-191071" > Pretreatment With P...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Pretreatment With P2Y12 Inhibitors in Patients With Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention : A Report From the Swedish Coronary Angiography and Angioplasty Registry

Jurga, Juliane (author)
Karolinska Institutet,Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden
Szummer, Karolina Elizabeth (author)
Department of Cardiology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Huddinge, Sweden,Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden
Lewinter, Christian (author)
Department of Cardiology, Karolinska Institutet and Karolinska University Hospital, C.L., L.M., Stockholm, Solna, Sweden,Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden
show more...
Mellbin, Linda (author)
Karolinska Institutet,Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden
Götberg, Matthias (author)
Department of Cardiology, Lund University Hospital, Skåne, Sweden,Lund Univ Hosp, Sweden
Zwackman, Sammy (author)
Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Kardiologiska kliniken US
Nilsson, Johan (author)
Umeå universitet,Kardiologi,Department of Cardiology, Umeå University and Umeå University Hospital,Umea Univ, Sweden; Umea Univ Hosp, Sweden
Völz, Sebastian, 1980 (author)
Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
Erlinge, David (author)
Department of Cardiology, Lund University Hospital, Skåne, Sweden,Lund Univ Hosp, Sweden
Persson, Jonas (author)
Department of Clinical Sciences, Danderyd University Hospital, Karolinska Institutet, Stockholm, Sweden,Danderyd Hosp, Sweden
Omerovic, Elmir, 1968 (author)
Gothenburg University,Göteborgs universitet,Wallenberglaboratoriet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Wallenberg Laboratory,Institute of Medicine, Department of Molecular and Clinical Medicine
Jernberg, Tomas (author)
Karolinska Institutet,Danderyd Hosp, Sweden
Venetsanos, Dimitrios (author)
Department of Cardiology, Karolinska Institutet and Karolinska University Hospital, C.L., L.M., Stockholm, Solna, Sweden,Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden
show less...
 (creator_code:org_t)
NLM (Medline), 2021
2021
English.
In: Circulation. Cardiovascular Interventions. - : NLM (Medline). - 1941-7640 .- 1941-7632. ; 14:11, s. 1086-1093
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • BACKGROUND: In patients with chronic coronary syndrome undergoing percutaneous coronary intervention, the optimal timing of P2Y12 inhibitors' administration is uncertain. We compared pretreatment versus treatment in the catheterization laboratory (In-Cathlab) in a real-world population.METHODS: In Swedish Coronary Angiography and Angioplasty Registry, all patients with chronic coronary syndrome undergoing coronary angiography and ad hoc percutaneous coronary intervention, between 2006 and 2017 were identified. Pretreatment was defined as P2Y12 inhibitor administration before coronary angiography, outside the catheterization laboratory. Outcomes were net adverse clinical events including death, myocardial infarction, stroke, or bleeding within 30 days of the index procedure and in-hospital bleeding.RESULTS: We included 26 814 patients, 8237 in the In-Cathlab, and 18 577 in the pretreatment group. In-Cathlab treatment compared with pretreatment was associated with lower risk for net adverse clinical event (4.2 versus 5.1%, adjusted hazard ratio 0.79 [0.63-0.99]), bleeding (2.3 versus 2.6%, adjusted hazard ratio, 0.76 [0.57-1.01]). and in-hospital bleeding (1.9 versus 2.1%, adjusted odds ratio, 0.70 [0.51-0.96]). The risk for death, myocardial infarction, or stroke did not significantly differ between the groups. Among the In-Cathlab treated patients, 41% received ticagrelor or prasugrel and 59% clopidogrel. Treatment with ticagrelor or prasugrel was associated with higher risk for net adverse clinical events (5.4% versus 3.4%, adjusted hazard ratio, 1.66 [1.12-2.48]), bleeding (3.4 versus 1.6%, adjusted hazard ratio, 2.14 [1.34-3.42]), and in-hospital bleeding (2.9 versus 1.2%, adjusted odds ratio, 2.24 [1.29-3.90]) but similar risk for death, myocardial infarction, or stroke, compared with clopidogrel.CONCLUSIONS: In patients with chronic coronary syndrome undergoing coronary angiography and ad hoc percutaneous coronary intervention, pretreatment with P2Y12 inhibitors, before arrival to the catheterization laboratory, was not associated with improved clinical outcomes but was associated with increased risk for bleeding. Our data support clopidogrel administration in the catheterization laboratory as the standard of care. Graphic Abstract: A graphic abstract is available for this article.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Keyword

angioplasty
clopidogrel
odds ratio
percutaneous coronary intervention
ticagrelor

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view